What does issuance of earnout shares amount mean?

This represents the value of equity shares issued as part of earnout provisions, typically related to acquisitions or performance milestones. It reflects a non-cash settlement of contingent liabilities using the company's own stock. Investors track this to assess potential dilution and the total cost of historical business combinations.

NewAmsterdam Pharma Company NAMS Issuance Of Earnout Shares Amount

Issuance Of Earnout Shares Amount at other companies

AvePoint, Inc.AVPT

$0-100%

DJT

Trump Media & Technology GroupDJT

$0—

AvePoint, Inc.AVPT

3T—

AvePoint, Inc.AVPT

$13.47M—

Dave, Inc.DAVE

-$3.19M-702%

Roivant SciencesROIV

$14.42M—

Other financials

Income statement

See full

Revenue$3.0M+2.1%

Operating income-$58.4M+15.2%

Net income-$48.4M-22.6%

EPS (diluted)-$0.40-17.6%

Balance sheet

See full

Cash & equivalents$457.6M-38.9%

Total debt$23.0K-94.1%

Total equity$665.2M-14.4%

Total assets$732.6M-10.5%

Cash flow

See full

Operating cash flow-$30.6M+16.1%

CapEx$38.0K+138%

Free cash flow-$30.6M+16.0%

Valuation

See full

Market cap$3.67B+63.7%

Profitability

See full

Operating margin-953.6%-3,536pp

Net margin-942.8%-3,477pp

FCF margin-630.1%-6,324pp

Returns & leverage

See full

Return on equity-29.5%-1.8pp

Current ratio9.8×-10.2×

Where this comes from

Reported directly by NewAmsterdam Pharma Company in its filing.

Tagged under the XBRL concept nams:IssuanceOfEarnoutSharesAmount.

The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about NewAmsterdam Pharma Company's issuance of earnout shares amount.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is NewAmsterdam Pharma Company's issuance of earnout shares amount?: NewAmsterdam Pharma Company (NAMS) reported issuance of earnout shares amount of $40.81M in Q1 2025.
What does issuance of earnout shares amount mean?: This represents the value of equity shares issued as part of earnout provisions, typically related to acquisitions or performance milestones. It reflects a non-cash settlement of contingent liabilities using the company's own stock. Investors track this to assess potential dilution and the total cost of historical business combinations.